Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized crossover bioequivalence study of subcutaneous tocilizumab formulations in healthy subjects
jRCT1080223096Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tocilizumab (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Pharmacokinetic bioequivalence between new and current commercial subcutaneous tocilizumab products. Started Feb 2016; status: completed.
02
Drugs
tocilizumab
Beyond the preview
Go deeper on jRCT1080223096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223096.